Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Analysis by 2029

Gamma-aminobutyric acid (GABA) receptor agonist market has been growing significantly across the globe. The market is expected to show an increased growth rate post COVID-19 as there are surging cases of the neurodegenerative disorders across he regions which will further boost the adoption of gamma-aminobutyric acid (GABA) receptor agonist.

Data Bridge Market Research analyses that the gamma-aminobutyric acid (GABA) receptor agonist market will grow at a CAGR of 8.2% during the forecast period of 2022 to 2029.

The rise in the neurodegenerative disorders such as the Alzheimer’s disease and Parkinson’s disease across the globe will result in the expansion of the growth rate of the market. Moreover, the vulnerable aging population is expected to expand the market’s growth within the forecasted period.

Moreover, the adoption of unhealthy lifestyle that increases the risk of evolving mental health disorders are also the growth determinants which bolster the growth of the market. Also, the availability of the treatment will further enhance the growth of gamma-aminobutyric acid (GABA) receptor agonist market.

North America dominates the gamma-aminobutyric acid (GABA) receptor agonist market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to due to high prevalence cases of CNS disorders and number of FDA approval drugs in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the focus of various global companies to expand their products in this particular region.

Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/global-gaba-receptor-agonist-market

Some of the major players operating in the gamma-aminobutyric acid (GABA) receptor agonist market are Sanofi, Mylan N.V., Teva Pharmaceutical Industries Ltd, Novartis AG, Aytu BioScience, Inc., Dr. Reddy’s Laboratories Ltd, Endo Pharmaceuticals Inc., Lupin, Johnson & Johnson Services, Inc, Lannett, Sun Pharmaceutical Industries Ltd, Cipla Inc, Aurobindo Pharma and Zydus Cadila among others.

Related Reports:

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Article source: https://article-realm.com/article/Sports-Recreation/42797-Gamma-aminobutyric-Acid-GABA-Receptor-Agonist-Market-Analysis-by-2029.html